Contents

Search

elbasvir

Indications: - in combination with grazoprevir for treatment-naive hepatitis C infection genotypes 1,4,6 Dosage: - 50 mg PO QD for 12 weeks in combination with grazoprevir 100 mg PO QD Adverse effects: - similar to placebo [1] Mechanism of action: - antiviral protease inhibitor, inhibits NS5A

General

antiviral protease inhibitor

References

  1. Zeuzem S et al Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic HCV Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. Published online 24 April 2015 PMID: 25909356 http://annals.org/article.aspx?articleid=2279766

Component-of

elbasvir/grazoprevir (Zepatier)